NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin

OBJECTIVES: This is a prospective study evaluating NEPA in patients with breast cancer (the NEPA group), who received (neo)adjuvant AC chemotherapy (consisting of doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2)). The primary objectives were to assess the efficacy and safety of NEPA in contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeo, Winnie, Lau, Thomas KH, Kwok, Carol CH, Lai, Kwai T, Chan, Vicky TC, Li, Leung, Chan, Vivian, Wong, Ashley, Soo, Winnie MT, Yeung, Eva WM, Wong, Kam H, Tang, Nelson LS, Suen, Joyce JS, Mo, Frankie KF
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304103/
https://www.ncbi.nlm.nih.gov/pubmed/31996363
http://dx.doi.org/10.1136/bmjspcare-2019-002037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304103/
https://www.ncbi.nlm.nih.gov/pubmed/31996363
http://dx.doi.org/10.1136/bmjspcare-2019-002037

Ejemplares similares